Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sponsors Seek One-Trial Approval Of Antibiotics For Drug-Resistant Bugs

Executive Summary

Antibiotic developers are urging FDA to approve medicines to treat drug-resistant microbes on the basis of a single trial, with other supportive clinical and preclinical data to be used as substantiating evidence.
Advertisement

Related Content

Trial Designs For Non-Cystic Fibrosis Bronchiectasis May Need Refinement
FDA Exploring Limited-Use Approvals For Antibiotics Based On Small Development Programs
FDA Continues To Clarify Antibiotic Requirements With New Guidance On Complicated UTI
Antibiotic Development Incentives Could GAIN Support From Pipeline Survey
Antibiotic Development Incentives Could GAIN Support From Pipeline Survey
Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again
Guidance In The Works For Unmet Need In Serious Bacterial Infections
PhRMA Urges FDA To Set Non-Inferiority Margin For Skin Infection Drugs
Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends Sole Primary Endpoint

Topics

Advertisement
UsernamePublicRestriction

Register

PS053824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel